July 16, 2018
We interviewed Dr. Peter de Keizer, a researcher who is engaged in studying senescent cells and designing therapies to destroy them in order to delay and prevent age-related diseases. Cleara Biotech is currently using his research to develop a senolytic peptide that accomplishes this via interfering with the interactions between p53 and FOXO4. Senescent cells...
July 09, 2018
Interest in therapies that remove senescent cells from the body, known as senolytics, has grown massively in the last year or so. There are now a number of companies actively developing senolytic therapies, including UNITY Biotechnology, Oisin Therapeutics, and Antoxerene. Recently, another company, Cleara Biotech, has arrived on the scene. We anticipated this last year...
